Henry Ford Health | Strategic Alliance Partners

We take cancer personally at Henry Ford Health. Patients at our ground-breaking cancer pavilion in Detroit—and at any of our other locations across Michigan—have the access to highly advanced treatments targeted to their personal needs. With precision medicine, we can determine the most effective treatment, based on an individual’s unique DNA. Leading-edge radiation technology takes personalization even further, allowing real-time dose adjustments as the targeted tumor changes. And every patient can count on us for personal attention and emotional support at every step of the way. Our 1,450 highly skilled doctors, researchers, nurse navigators and other healthcare specialists provide world class cancer care to thousands of patients each year. Our new cancer pavilion is the heart of Henry Ford Cancer, which has locations across southeast and south central Michigan. With five hospital locations, seven additional outpatient cancer centers and dozens of aligned doctor’s offices, we can offer care close to home. We are one strong, integrated team, ensuring patients have access to the latest advances in cancer treatment, research, clinical trials and support throughout their journey. We have treated people from every state in the U.S. and every continent in the world.

henryford.com/services/cancer

Connect with us:

Latest from Henry Ford Health

Frontline Amivantamab/Lazertinib Combo Shows Trend of OS Benefit in Advanced EGFR+ NSCLC

September 09, 2024

Article

When compared with osimertinib, amivantamab plus lazertinib showed a trend toward favorable overall survival in patients with EGFR-mutant advanced NSCLC.

Increasingly Targeted ADCs Drive NSCLC Treatment Innovations

April 12, 2024

Article

Shirish M, Gadgeel, MD, highlights key treatment advances achieved with antibody-drug conjugates in non–small cell lung cancer.

Dr Hwang on Considering AEs Associated With FDA-Approved Agents in Nonmetastatic Prostate Cancer

September 15, 2023

Video

Clara Hwang, MD, discusses adverse effects associated with FDA-approved agents for patients with nonmetastatic prostate cancer.

Dr Hwang on Unmet Needs Remaining in Nonmetastatic Prostate Cancer

September 13, 2023

Video

Clara Hwang, MD, discusses unmet needs in patients with nonmetastatic prostate cancer who then progress on novel agents and develop metastatic disease.

Dr Gadgeel on Adagrasib Monotherapy in KRAS G12C–Mutated NSCLC

September 11, 2023

Video

Shirish M. Gadgeel, MD, discusses 2-year follow-up data from the phase 1/2 KRYSTAL-1 trial in patients with advanced or metastatic non–small cell lung cancer harboring KRAS G12C mutations.

Adagrasib Yields Durable Benefit for Patients With KRAS G12C–Mutant NSCLC

September 10, 2023

Article

Adagrasib monotherapy provided durable efficacy for patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer, according to 2-year follow-up data from the phase 1/2 KRYSTAL-1 trial.

Dr Hwang on Risk-Stratification Factors in Nonmetastatic Prostate Cancer

September 06, 2023

Video

Clara Hwang, MD, discusses risk stratification methods used to assess the risk of metastatic disease in patients with nonmetastatic prostate cancer.

Henry Ford Health + MSU Health Sciences Funds Five Cancer Research Grants to Advance Cancer Medicine, Combat Health Disparities

January 31, 2023

Article

Henry Ford Health + Michigan State University Health Sciences announced its funding of 5 cancer research grants of up to $100,000 each. These 5 grants follow an initial wave of funding from the partnership, in which 18 pilot grants of up to $25,000 each were funded in May 2022.

Henry Ford Health First in Michigan to Offer Multi-Cancer Early Detection Blood Test

January 27, 2023

Article

Henry Ford Health is the first healthcare provider in Michigan to offer Galleri®, GRAIL’s Multi-Cancer Early Detection blood test.

Henry Ford Hospital Earns Prestigious Recognition from National Accreditation Program for Rectal Cancer

January 10, 2023

Article

Henry Ford Hospital has earned a three-year accreditation from the National Accreditation Program for Rectal Cancer, which was developed through a collaboration between the OSTRiCh consortium and the Commission on Cancer, a quality program of the American College of Surgeons.

Study Shows Promising Safety, Patient Outcomes Data for MRI-Guided Adaptive Radiation Therapy to Treat Pancreatic Cancer

January 03, 2023

Article

Findings from a recent prospective study show promising safety and patient outcomes data for locally advanced and borderline resectable pancreatic cancer treatment using ablative Stereotactic MRI-Guided On-table Adaptive Radiation Therapy, also known as SMART.

KRAS Mutations Represent Important Target in Expanding Treatment of Pancreatic Cancer

June 30, 2022

Article

Philip A. Philip, MD, PhD, FRCP, discusses unmet needs for patients with pancreatic cancer, emerging targets and agents in the space, and his hopes for future developments in the field.